Pharmacodynamics (PD) is an area of pharmacology concerned with the relationship between a drug’s concentration at the site of action and the resulting effect, and to measurement of that ...

The target of treatment remains as sustained remission (according to the ACR-EULAR definition) or low disease activity, and the major focus continues to be pharmacological therapy with ...

Sepsis is defined as a life-threatening dysfunction due to a dysregulated host response to infection. It is a common and complex syndrome and is the leading cause of death in intensive care units. The ...

Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product ...

Fibroblast growth factors (FGFs) signal through FGF receptor tyrosine kinases to regulate a wide range of biological processes during development and adulthood. FGF receptors (FGFRs) are involved ...

aMedical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil bGrupo de Pesquisa Clínica em Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil ...

BNA™ Metrics as Cognitive Biomarkers: Baseline brain activation latencies, as measured through Firefly's BNA™ technology, ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...

Christine M. Slover, PharmD, Infectious Diseases Fellow, Keith A. Rodvold, PharmD and Larry H. Danziger, PharmD, Professor, Department of Pharmacy Practice ...

The purpose of the course is to introduce the use of biomarkers in clinical research today and tomorrow, as well as presenting the principles for their quantification in selected analyses. Such ...

Objective Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treating gout and asymptomatic hyperuricaemia. This study evaluated the pharmacodynamics, ...